About Aerie Pharmaceuticals

Join the VISIONaerieS™

Inspiration, imagination, and innovation. We share this passion for finding new approaches to protecting vision. United by great science, deep clinical insight, and a singular focus on your ophthalmic needs, we see the possibilities ahead and invite you to join us in creating the future of eye care.

Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialisation of first-in-class therapies for the treatment of glaucoma and other diseases of the eye.
 
See the future of eye care with Aerie.
 

Aerie Pharmaceuticals Jobs: 6

Our Strategy:

• The first new proposed mechanisms of action (MOA) in a generation to treat patients with glaucoma, the largest prescription market in ophthalmology.
• Designed to potentially reduce elevated intraocular pressure (IOP), the cause of vision loss in open-angle glaucoma.
• Two late development-stage product candidates – Rhopressa™ (netarsudil ophthalmic solution) 0.02% and Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%.
• Both product candidates are eye drops taken once a day in the evening.
• Each product candidate has potential multiple mechanisms of action, including the novel targeting of the diseased tissue, or main drain in the eye – the source of elevated IOP; potential for disease modification.
• Blockbuster revenue potential in a current $4.7 billion market in the US, Europe and Japan, which is expected to grow to more than $8 billion by 2023.
• All product candidates fully owned by Aerie with patents through to at least 2030.    

Aerie Athlone:

Aerie currently employs 120 located in the US and EU with plans to expand to 160 in 2017 and beyond in 2018. Headquartered in Irvine – CA we are also located in Bedminster - NJ, Raleigh/Durham - NC, Dublin & Malta. We are building our broader organisation in readiness for the commercialisation of our products, and the supply of same via our first manufacturing facility located in Athlone, Ireland.

Aerie have acquired the 2,650m2 IDA Advanced Technology Building in Athlone and will embark on an initial investment of $60m. A fast track start-up, our new sterile filling plant will be designed, constructed and validated for the global supply of our ophthalmic products with a target first regulatory approval & commercialization in early 2020. The plant will include end to end operations – compounding, sterile filling, and packaging with all support capabilities (QC labs, warehousing, etc.).

Our Core Values: